MRNA
Moderna, Inc.
There isn't enough reported data to score MRNA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MRNA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
MRNA's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MRNA PE Valuation
MRNA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MRNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MRNA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MRNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$7.09 | +$0.98 |
| Q2 2026 | -$7.98 | -$0.45 |
| Q1 2026 | -$8.14 | +$0.59 |
| Q4 2025 | -$7.26 | +$2.02 |
| Q3 2025 | -$8.07 | -$2.33 |
| Q2 2025 | -$7.53 | +$7.77 |
| Q1 2025 | -$8.73 | +$6.86 |
| Q4 2024 | -$9.28 | +$3.05 |
MRNA is still losing money, but far less than before: $7.09 per share over the past year, against $15.59 at its worst in early 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MRNA on earnings quality, reporting a profit while its opponent remains loss making.
MRNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +29% |
| Q2 2026 | $145M | +2.1% |
| Q1 2026 | $389M | +260% |
| Q4 2025 | $678M | -30% |
| Q3 2025 | $1B | -45% |
| Q2 2025 | $142M | -41% |
| Q1 2025 | $108M | -35% |
| Q4 2024 | $966M | -66% |
MRNA's revenue is recovering but still below its 2021 peak: $1.3B last quarter, up 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.9% | +36 points |
| Q2 2026 | -562% | +77 points |
| Q1 2026 | -357% | +615 points |
| Q4 2025 | -126% | +2.6 points |
| Q3 2025 | -26% | -22 points |
| Q2 2025 | -639% | -73 points |
| Q1 2025 | -972% | -214 points |
| Q4 2024 | -129% | -129 points |
MRNA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MRNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
MRNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$726M |
| Q2 2026 | -$563M | +$359M |
| Q1 2026 | -$692M | +$462M |
| Q4 2025 | $891M | +194% |
| Q3 2025 | -$880M | +$837M |
| Q2 2025 | -$922M | +$534M |
| Q1 2025 | -$1.2B | +$31M |
| Q4 2024 | $303M | -25% |
MRNA has burned cash in six of the last eight quarters: −$2B over the past year, against −$2.7B the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MRNA on cash generation, producing positive trailing cash flow while its opponent burns cash.
MRNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +32M shares |
| 1 year | +10% | +40M shares |
| 3 years | +13% | +49M shares |
| 5 years | -0.9% | -4M shares |
| Available history | +30% | +99.2M shares |
MRNA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $1M |
| Q2 2023 | $628M |
| Q1 2023 | $526M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MRNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2023 | -4.4x | Net Cash |
| Q1 2023 | -0.7x | Net Cash |
| Q4 2022 | -0.3x | Net Cash |
| Q3 2022 | -0.2x | Net Cash |
| Q2 2022 | -0.2x | Net Cash |
| Q1 2022 | -0.3x | Net Cash |
| Q4 2021 | -0.5x | Net Cash |
| Q3 2021 | -0.7x | Net Cash |
MRNA has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MRNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.5 | Overbought |
| Stochastic | 85.1 | Overbought |
MRNA's weekly RSI is 71 (overbought) and its Stochastic is 85 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MRNA PE vs Healthcare Sector
| Metric | MRNA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MRNA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MRNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $217.4 | 6.4% above |
| 20 week MA | $145.4 | 59% above |
| 50 week MA | $86.0 | 169% above |
| 100 week MA | $57.8 | 300% above |
| 200 week MA | $82.4 | 181% above |
MRNA has climbed back above all five of its weekly moving averages, and it's now 181% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
MRNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.5 | $123.4 | +532% |
| 2021 | $123.4 | $250.0 | +103% |
| 2022 | $250.0 | $199.1 | -20% |
| 2023 | $199.1 | $99.5 | -50% |
| 2024 | $99.5 | $40.1 | -60% |
| 2025 | $40.1 | $31.2 | -22% |
| 2026 YTD | $31.2 | $231.4 | +642% |
MRNA has the edge over OSCR on returns for 2026, with the stronger performance.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.